Urogenital System

Suheil Zmeili; MD, PhD
Faculty of Medicine
Department of Pharmacology
University of Jordan
Pharmacological properties of:

- Diuretics
- Antifungal agents
- Oxytocin (drugs acting on uterus) & ADH
- GnRH; LH; FSH
- Estrogens; antiestrogens; progestins; antiprogestins; contraception
ILO’S

- Available preparations and their pharmacological properties
- Mechanism of action
- Clinical uses
- Major side effects
Diuretics (Saluretics)
Diuretics increase urine excretion mainly by ↓ reabsorption of salts and water from kidney tubules

These agents are ion transport inhibitors that decrease the reabsorption of Na+ at different sites in the nephron, thus increasing the volume of the urine and often change its pH as well as the ionic composition of the urine and blood

Water, digitalis, caffeine and theophylline have diuretic activity, but are not diuretics
General clinical uses:
- Hypertension
- Edema of heart, renal or liver failure
- Pulmonary edema
- ↑ intracranial pressure (Mannitol)
- ↑ intraocular pressure=glaucoma (CA inhibitors) (acetazolamide)
- Hypercalcemia (Furosemide=Frusemide)
- Idiopathic hypercalciuria (Thiazides)
- Inappropriate ADH secretion (Furosmide)
- Nephrogenic diabetes insipidus (Thiazides)
General consideration

- Basic knowledge of renal physiology particularly salt and water movements (absorb., reabsorb and tubular secretion) and cotransporter systems is mandatory

- Diuretics, in short, are widely used in the management of any condition associated with salt and water retention

- Diuretics act at different sites of the nephron (the basic unit of the kidney)
- Diuretics are highly effective, relatively safe and cheap
- Diuretics are considered **first-line therapy** for most hypertensive pts
  - Initial antihypertensive therapy without compelling indications
  - JNC 6: Diuretic or a beta-blocker
  - JNC 7: Thiazide-type diuretics

JNC 7=The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Accumulating evidence proves that in hypertensive patients diuretics, particularly thiazides decrease the risk of cardiovascular disease, fatal and nonfatal MI and stroke.

**ALLHAT** study:

*Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial*

{Involved more than 40,000 hypertensive pts; 8 yrs study started in 1994}

Many other antihypertensive agents are combined with diuretics in the same tablet.
- Diuretics MOA:
  - Simply by increasing urine output → ↓ plasma and stroke volume → ↓ CO → ↓ BP

The initial ↓ in CO leads to ↑ peripheral resistance, but with chronic use extracellular fluid and plasma volume return to normal and peripheral resistance ↓ to values lower than those observed before diuretic therapy

- Thiazides are also believed to have direct vasodilating effect
**Diuretic therapy cautions**

- Excessive diuretic usage may lead to a compromise of the effective arterial blood volume with reduction in perfusion of vital organs.

Therefore, the use of diuretics to mobilize edema requires careful monitoring of the patient's hemodynamic status and an understanding of the pathophysiology of the underlying condition.
Cont. diuretic cautions,

- The decrease in blood volume can lead to hypotension and collapse

- Blood viscosity rises due to an increase in erythro-and thrombocyte concentration, which could lead to an increased risk of intravascular coagulation or thrombosis
- Many diuretics (loop diuretics, thiazides, amiloride, and triamterene) exert their effects on specific membrane transport proteins in renal tubular epithelial cells,

- Other diuretics exert osmotic effects that prevent water reabsorption (mannitol),

- Still others inhibit enzymes (acetazolamide),

- Some others interfere with hormone receptors in renal epithelial cells (spironolactone)
Classification of diuretics

Diuretics are usually categorized by their site of action in the kidney; their MOA and to a lesser extent by their potency.

Osmotic diuretics

Mannitol

It is a sugar, not absorbed by kidney tubules, has no systemic effects and not metabolized.

↑ osmotic pressure in kidney tubules → withdraw H₂O → ↑ urine excretion by ↓ H₂O reabsorption with little ↑ in NaCl excretion.
- Mannitol increases urine volume & can be used to maintain urine volume and to prevent anuria

- Reduces intraocular pressure before ophthalmologic procedures

- Promotes removal of renal toxins

- Facilitates clearance of mucus in patients with bronchiectasis

Site of action: Proximal convoluted tubule

Major clinical use: ↑ intracranial pressure, given I.V
Mannitol toxicity

- Extracellular volume expansion

Mannitol is rapidly distributed in the extracellular compartment and extracts water from cells

- Headache, nausea, and vomiting are commonly observed in patients treated with osmotic diuretics

- Dehydration, hyperkalemia and hypernatremia
Carbonic anhydrase inhibitors

Acetazolamide

Carbonic anhydrase enzyme is important enzyme responsible for reabsorption of Na\(^+\)HCO\(_3\)\(^-\) from proximal convoluted tubules and for formation of aqueous humor (fluid of the eye)

Inhibition of carbonic anhydrase enzyme increases urine outflow and decreases formation of aqueous humor
Acetazolamide inhibits the enzyme carbonic anhydrase → ↓ Na⁺HCO₃ reabsorption and thus H₂O → ↑ urine outflow

Site of action: Proximal convoluted tubules

Major clinical use: glaucoma

Acetazolamide is effective orally and as an ophthalmic drops

Dorzolamide & Brinzolamide are other available topically (ophthalmic drops) active carbonic anhydrase inhibitors
** Other uses to acetazolamide:

- **Urinary Alkalization**

Renal excretion of weak acids can be enhanced by increasing urinary pH with carbonic anhydrase inhibitors

- **Prophylaxis and Rx of Acute Mountain Sickness** characterized by weakness, dizziness, insomnia, headache, nausea, cerebral and pulmonary edema that can occur in mountain travelers who rapidly ascend above 3000 m (mechanism unknown)

- Absence seizures and myoclonic seizures
- **Side effects to CA inhibitors:**

  - Hyperchloremic metabolic acidosis
    
    Acidosis results from chronic reduction of body bicarbonate stores

  - Renal Stones
    
    Calcium salts are relatively insoluble at alkaline pH
Thiazides and thiazide-like diuretics

- Least expensive
- Low to moderate efficacy diuretics
- The most frequently used diuretics
- Differ in their $t_{1/2}$, DOA and potency, have similar MOA
Thiazides
Bendroflumethiazide
Benzthiazide
Chlorthiazide
Hydrochlorothiazide
Hydroflumethiazide
Methyclothiazide
Polythiazide
Trichlormethiazide

Thiazide-like drugs
Chlorthalidone
Indapamide
Metolazone
Quinethazone
Most widely used thiazides, thiazide-like diuretics:

- Hydrochlorothiazide
- Chlorthalidone
- Indapamide
**Thiazide MOA:**

a. Inhibition of thiazide-sensitive $\text{Na}^+ / \text{Cl}^-$ transporter in distal convoluted tubule, thus inhibiting $\text{Na}^+$ reabsorption $\rightarrow \uparrow \text{Na}^+$, $\text{K}^+$, $\text{Cl}^-$, $\text{HCO}_3^-$ and $\text{H}_2\text{O}$ excretion

Thiazides $\uparrow \text{Ca}^{++}$ reabsorption

b. Little carbonic anhydrase (CA) inhibitory effect
c. Direct vasodilating effect (**Indapamide** has been observed for its pronounced vasodilating effect)

d. ↓ response of blood vessels to NE

Their early hypotensive effect is related to a reduction in blood volume, their long-term effect is related to a reduction in peripheral vascular resistance
Thiazides lead to ≈ 5-10% loss of filtered Na⁺

↑ in dose will not lead to further increase in their diuretic effect (low ceiling)

They are ineffective in pts with impaired renal function or pts with GFR< 20 ml/min

They are highly effective in lowering BP when combined with other antihypertensive drugs (synergistic effect)
Thiazides kinetics:

Thiazides are usually given orally (Chlorthiazide may be given I.V), strongly bind plasma albumin, reach kidney tubules via a specific secretory mechanism (not filtered) and eliminated mostly unchanged by the kidney (small fraction biliary excretion)
- Thiazides site of action:
  DCT
- Clinical uses to thiazides:
  - Hypertension
  - Edema of HF; liver cirrhosis...etc
  - Nephrogenic diabetes insipidus
  - Hypercalciuria
- Side effects to thiazides:
  - Weakness; muscle cramps
  - Erectile dysfunction
  - Hyperglycemia
  - Hyperlipidemia (↑ LDL, ↑ TG’s)
  - Hypercalcemia
  - Pancreatitis
- Hypokalemia & hypomagnesemia

Most frequent and dangerous side effect →
muscle weakness and serious cardiac
arrhythmias

Pts at high risk are those with:

LVH; previous hx of MI; previous hx of
cardiac arrhythmias & pts who are on
digoxin therapy
- Hyperuricemia

Thiazides could precipitate gout

The effect of thiazides on uric acid is dose dependent:

Low doses → hyperuricemia

Large doses → ↓ uric acid reabsorption
• High ceiling, loop, high efficacy diuretics:
  Furosemide (Frusemide)  O; I.V
  Bumetanide               O; I.V
  Ethacrynic acid          O; I.V
  Torsemide                O; I.V

The strongest diuretics, have rapid OOA and short DOA

• Site of action

Thick segment of ascending loop of Henle
Loop diuretics MOA

Inhibition of $\text{Na}^+ / \text{K}^+ / 2\text{Cl}^-$ transporter leading to 10-25% loss of filtered $\text{Na}^+$

$\uparrow$ dose $\rightarrow$ $\uparrow$ diuretic effect; over-treatment $\rightarrow$ dehydration

Effective even at GFR below 10 ml/min (loop diuretics are most effective in patients with renal insufficiency = creatinine level $> 2.5$ mg/dl) or resistant cases to other diuretics
Loop diuretics ↑ excretion of Na⁺, Cl⁻, K⁺, H⁺, H₂O and HCO₃⁻ (weak CA inhibitory effect)

They are effective orally (OOA 30-60 min; DOA ≈ 6 hrs) and parenterally (OOA 5 min; DOA ≈ 2 hrs)

They are albumin bound, eliminated in urine by filtration and tubular secretion and 1/3 rd of oral dose is excreted in bile
Clinical uses to loop diuretics:
- Acute pulmonary edema
- Edematous states (ascitis; CHF; renal failure...etc)
- Considered 1st line therapy in patients with CHF
- Hypertension
- Hypercalcemia
- Syndrome of Inappropriate ADH secretion
Side effects to loop diuretics:

- Hypokalemia; hypomagnesemia
- Hypocalcemia
- Irreversible ototoxicity (usually dose related and more common with I.V administration)
- Dehydration; hyperglycemia; hyperuricemia
- Headache; dizziness (due to ↓ in BP)
- Allergic reactions; alkalosis
Potassium sparing, low efficacy diuretics;

a. Aldosterone antagonists

Spironolactone; Eplerenone

Aldosterone → ↑ synthesis of Na\(^+\)-K\(^+\) ATPase
→ ↑ Na\(^+\) reabsorption, ↓ reabsorption of K\(^+\) (↑ excretion of K\(^+\) & H\(^+\))

Aldosterone antagonists → ↑ Na\(^+\) excretion & ↓ K\(^+\) excretion
Site of action of potassium sparing diuretics

Collecting ducts

Only effective in presence of aldosterone
(competitive antagonists)

Given orally; have delayed OOA

Weak diuretics, usually combined with other antihypertensives or thiazides

Have great benefit in improving myocardial function in patients with heart failure

Eplerenone is more potent than Spironolactone
Clinical uses to potassium sparing diuretics:

- Hypertension
- CHF
- Hyperaldosteronism (1° or 2°)
- Hypokalemia
- Hirsutism (antiandrogenic effect)
Side effects to potassium sparing diuretics:
- Hyperkalemia → cardiac arrhythmias
  More common in patients with diabetes, chronic renal disease or patients on ACE inhibitors
  More severe with eplerenone
- Gynecomastia in ♂’s (rare with Eplerenone)
- Breast tenderness in ♀’s (rare with Eplerenone)
b. None steroidal potassium sparing diuretics: Amiloride; Triamterene

- **Site of action:** DCT, collecting duct
- **MOA**

  Blockade of epithelial Na\(^+\) channels → ↓ Na\(^+\) reabsorption, ↓ K\(^+\) excretion

  Orally effective and available alone or combined with thiazides
Clinical uses:
- Hypertension
- Hypokalemia

Side effects:
- Hyperkalemia
- Renal tubular damage especially reported following the use of Triamterene + Hydrochlorothiazide
The problem of diuretic-induced hypokalemia:
- Thiazide or loop diuretic + oral $K^+$ supplement
- Combine thiazide or loop diuretic with a $K^+$ sparing diuretic
** Unlike thiazide diuretics, loop and $K^+$ sparing diuretics have no effects on blood lipids
Diuretic resistance or refractoriness (Therapeutic Failure):
- Continued ingestion of salt
- Impairment of organic acid secretion mechanisms in the proximal tubules due to: diseases or drugs
- Secondary hyperaldosteronism
- Lowered renal blood flow $\rightarrow \uparrow \text{Na}^+$ reabsorption (postdiuretic salt retention)
- Lowered bioavailability of the drug

Management of diuretic resistance
Restriction of sodium intake, changes in dose, changes in timing, and combination of diuretic therapy
Diuretics
1. Acetazolamide
2. Osmotic agents (mannitol)
3. Loop agents (e.g., furosemide)
4. Thiazides
5. Aldosterone antagonists
6. ADH antagonists

Source: Katzung BG: Basic & Clinical Pharmacology, 10th Edition:
http://www.accessmedicine.com
Copyright © The McGraw-Hill Companies, Inc. All rights reserved.